 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| LBL-024 / Leads Biolabs
Enrollment change, Metastases: A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma (clinicaltrials.gov) - Aug 1, 2024
P1/2, N=118, Recruiting, Sponsor: Nanjing Leads Biolabs Co.,Ltd
N=68 --> 118
- || LBL-024 / Leads Biolabs
Trial completion date, Trial primary completion date: A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors (clinicaltrials.gov) - May 21, 2024
P1/2, N=396, Recruiting, Sponsor: Nanjing Leads Biolabs Co.,Ltd
N=68 --> 118 Trial completion date: Jan 2025 --> Dec 2026 | Trial primary completion date: Jul 2024 --> Dec 2026
- LBL-024 / Leads Biolabs
A novel and uniquely designed bispecific antibody (LBL-024) against PD-L1 and 4-1BB in patients with advanced malignant tumors and neuroendocrine carcinoma: A report of safety and robust efficacy of LBL-024 monotherapy in phase I/II, first-in-human, open-label, multicenter, dose escalation/expansion study. (Hall D2) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3463;
P1/2
The efficacy observed in EP-NEC is significantly higher than the historic reports with immunotherapy (?10%) and chemotherapy (about 18%). The extremely robust efficacy and good safety profile support a pivotal study for accelerated development of EP-NEC, the highly unmet medical needs and deadly disease.
- ||| LBL-024 / Leads Biolabs
Enrollment open, Metastases: A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma (clinicaltrials.gov) - Jan 3, 2024
P1/2, N=68, Recruiting, Sponsor: Nanjing Leads Biolabs Co.,Ltd
The extremely robust efficacy and good safety profile support a pivotal study for accelerated development of EP-NEC, the highly unmet medical needs and deadly disease. Not yet recruiting --> Recruiting
- |||| LBL-024 / Leads Biolabs
New P1/2 trial, Metastases: A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma (clinicaltrials.gov) - Dec 6, 2023
P1/2, N=68, Not yet recruiting, Sponsor: Nanjing Leads Biolabs Co.,Ltd
- ||| LBL-024 / Leads Biolabs
Enrollment change, Metastases: A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors (clinicaltrials.gov) - Feb 13, 2023
P1/2, N=370, Recruiting, Sponsor: Nanjing Leads Biolabs Co.,Ltd
Not yet recruiting --> Recruiting N=264 --> 370
- |||| LBL-024 / Leads Biolabs
Enrollment open, Metastases: A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors (clinicaltrials.gov) - Feb 9, 2022
P1/2, N=264, Recruiting, Sponsor: Nanjing Leads Biolabs Co.,Ltd
N=264 --> 370 Not yet recruiting --> Recruiting
- ||||| LBL-024 / Leads Biolabs
New P1/2 trial, Metastases: A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors (clinicaltrials.gov) - Dec 28, 2021
P1/2, N=264, Not yet recruiting, Sponsor: Nanjing Leads Biolabs Co.,Ltd
- LBL-024 / Leads Biolabs
[VIRTUAL] LBL-024, an anti-PD-L1 and 4-1BB bispecific antibody with highly differentiated binding affinity, shows anti-tumor efficacy in a mouse tumor model () - Mar 11, 2021 - Abstract #AACR2021AACR_3287;
LBL-024, an anti-PD-L1 and 4-1BB bispecific antibody was shown a great synergetic anti-tumor efficacy in a mouse tumor model, more effective than the antibodies targeting either PD-L1 or 4-1BB alone. With highly differentiated binding affinity between two molecules, the efficacy and toxicity could be well balanced, to avoid the potential toxicity of systemic activation of 4-1BB, hence a promising bispecific antibody for further clinical development.